Cargando…

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody therapy is based on the determination of their RAS mutation status—a strongly negative predictive factor—since the protein target, EGFR, is not a reliable predictor of therapeutic response. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uhlyarik, Andrea, Piurko, Violetta, Papai, Zsuzsanna, Raso, Erzsebet, Lahm, Erika, Kiss, Edina, Sikter, Marta, Vachaja, Jozsef, Kenessey, Istvan, Timar, Jozsef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139947/ https://www.ncbi.nlm.nih.gov/pubmed/32155907 http://dx.doi.org/10.3390/cancers12030614

Ejemplares similares

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer
por: Cserepes, Mihály, et al.
Publicado: (2022)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

On-Target Side Effects of Targeted Therapeutics of Cancer
por: Tímár, József, et al.
Publicado: (2022)

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
por: Kenessey, István, et al.
Publicado: (2016)

The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma
por: Barbai, Tamás, et al.
Publicado: (2015)

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021)

Molecular epidemiology and diagnostics of KRAS mutations in human cancer
por: Timar, Jozsef, et al.
Publicado: (2020)

Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression
por: Bánky, Balázs, et al.
Publicado: (2012)

Demonstration of a Melanoma-Specific CD44 Alternative Splicing Pattern That Remains Qualitatively Stable, but Shows Quantitative Changes during Tumour Progression
por: Raso-Barnett, Livia, et al.
Publicado: (2013)

Characterization of the inflammatory cell infiltrate and expression of costimulatory molecules in chronic echinococcus granulosus infection of the human liver
por: Vatankhah, A., et al.
Publicado: (2015)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
por: Balko, Justin M, et al.
Publicado: (2009)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy
por: Ladányi, Andrea, et al.
Publicado: (2022)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
por: Barmettler, Hanna, et al.
Publicado: (2012)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases
por: Virág, József, et al.
Publicado: (2016)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

KIT Mutation Incidence and Pattern of Melanoma in Central Europe
por: Doma, V., et al.
Publicado: (2019)

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
por: Greene, Michelle K., et al.
Publicado: (2020)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer
por: Chen, Baomin, et al.
Publicado: (2020)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
por: Markóczy, Zsolt, et al.
Publicado: (2018)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8f4cpvrljo9jhtf1op5meh6n4a